Hemostatic Abnormalities and Liver Diseases

ABSTRACT

Professor Eberhard F. Mammen greatly contributed to the understanding of the relationship between hemostatic abnormalities and liver diseases. The physiology of the hemostatic system is closely linked to liver function because the liver parenchymal cells produce most of the factors of the clotting and fibrinolytic systems. Acute or chronic hepatocellular diseases and hepatic failure including liver cirrhosis, vitamin K deficiency, liver surgery including liver transplantation, and sclerotherapy of bleeding esophageal varices, which were classified by Prof. Mammen, show various hemostatic abnormalities in the coagulation system, fibrinolytic system, platelets, and the reticuloendothelial system. Hemostatic abnormalities in patients with hepatic failure or in those that have undergone liver surgery are similar to those in disseminated intravascular coagulation. Prof. Mammen also contributed to the study of vitamin K–dependent clotting factors, antithrombin, and hemostatic molecular markers. Partly based on this work, the prothrombin time–international normalized ratio, several hemostatic molecular markers, and antithrombin therapy have been recently developed for the diagnosis and treatment of thrombosis.

KEYWORDS

Liver disease - hemostasis - vitamin K deficiency - disseminated intravascular coagulation

REFERENCES

• 1 Mammen E F. Coagulopathies of liver disease.  Clin Lab Med. 1994;  14 769-780
• 2 Mammen E F. Coagulation defects in liver disease.  Med Clin North Am. 1994;  78 545-554
• 3 Mammen E F. Coagulation abnormalities in liver disease.  Hematol Oncol Clin North Am. 1992;  6 1247-1257
• 4 Mammen E F. Blood coagulation disorders in liver diseases.  Dtsch Med Wochenschr. 1970;  95 2241-2242
• 5 Carlier M, Van Obbergh L J, Veyckemans F et al.. Hemostasis in children undergoing liver transplantation.  Semin Thromb Hemost. 1993;  19 218-222
• 6 Matsumoto T, Wada H, Nishiyama H et al.. Hemostatic abnormalities and changes following bone marrow transplantation.  Clin Appl Thromb Hemost. 2004;  10 341-350
• 7 Stafford D W. The vitamin K cycle.  J Thromb Haemost. 2005;  3 1873-1878
• 8 Aljabiri M R, Lodato F, Burroughs A K. Surveillance and diagnosis for hepatocellular carcinoma.  Liver Transpl. 2007;  13 S2-S12
• 9 Tripodi A, Chantarangkul V, Mannucci P M. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions.  J Thromb Haemost. 2008;  6 243-248
• 10 Akiyama K, Nakamura K, Makino I et al.. Antithrombin III producing hepatocellular carcinoma.  Thromb Res. 1993;  72 193-201
• 11 Koike C, Hayakawa Y, Niiya K, Sakuragawa N, Sasaki H. The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1.  Thromb Haemost. 1996;  75 298-302
• 12 Mammen E F. Antithrombin: its physiological importance and role in DIC.  Semin Thromb Hemost. 1998;  24 19-25
• 13 Mammen E F. Clinical relevance of antithrombin deficiencies.  Semin Hematol. 1995;  32(Suppl 2) 2-6
• 14 Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients.  Semin Thromb Hemost. 1998;  24 293-297
• 15 Hirose K, Okajima K, Uchiba M, Nakano K Y, Utoh J, Kitamura N. Antithrombin reduces the ischemia/reperfusion-induced spinal cord injury in rats by attenuating inflammatory responses.  Thromb Haemost. 2004;  91 162-170
• 16 Warren B L, Eid A, Singer P et al.. KyberSept Trial Study Group: caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878
• 17 Kienast J, Juers M, Wiedermann C J et al.. KyberSept investigators: treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.  J Thromb Haemost. 2006;  4 90-97
• 18 Sakuragawa N. Regulation of thrombosis and hemostasis by antithrombin.  Semin Thromb Hemost. 1997;  23 557-562
• 19 Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit.  Am J Hematol. 2004;  76 225-229
• 20 Griffin G C, Mammen E F, Sokol R J, Perrotta A L, Stoyanovich A, Abildgaard C F. Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage.  Am J Pediatr Hematol Oncol. 1993;  15 328-330
• 21 Koyama T, Kakishita E, Nakai Y, Okamoto E. Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.  Am J Hematol. 1991;  38 90-94
• 22 Kuter D J, Begley C G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.  Blood. 2002;  100 3457-3469
• 23 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
• 24 Faeh M, Hauser S P, Nydegger U E. Transient thrombopoietin peak after liver transplantation for end-stage liver disease.  Br J Haematol. 2001;  112 493-498
• 25 Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.  Int J Hematol. 2002;  75 25-34
• 26 Ko S, Okano E, Kanehiro H et al.. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.  Liver Transpl. 2006;  12 859-869
• 27 Taylor Jr F B, Toh C H, Hoots K, Wada H, Levi M. Towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 1327-1330
• 28 Wada H. Disseminated intravascular coagulation.  Clin Chim Acta. 2004;  344 13-21
• 29 Soria J, Soria C, Ryckewaert J J, Samama M, Thomson J M, Poller L. Study of acquired dysfibrinogenaemia in liver disease.  Thromb Res. 1980;  19 29-41
• 30 Hoak D R, Mammen E F, Banerjee S K, Kaldor G. A fully automated immuno-turbidimetric determination of fibrin(ogen) degradation products.  Thromb Res. 1986;  44 1-10
• 31 Wada H, Kobayashi T, Abe Y et al.. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis.  J Thromb Haemost. 2006;  4 1253-1258
• 32 de Moerloose P, Palareti G, Aguilar C, Legnani C, Reber G, Peetz D. A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.  Thromb Haemost. 2008;  100 505-512
• 33 Roffi L, Colloredo G, Pioltelli P et al.. Gruppo Epatologico Lombardo. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.  Antivir Ther. 2008;  13 663-673
• 34 Wilson R F, Mammen E, Walt A J. Eight years of experience with massive blood transfusions.  J Trauma. 1971;  11 275-285
• 35 Jones A L, Hulett M D, Parish C R. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems.  Immunol Cell Biol. 2005;  83 106-118
• 36 Gando S, Iba T, Eguchi Y for the Japanese Association for Acute Medicine Disseminated Intravascular Coagulation et al. (JAAM DIC) Study Group: a multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria.  Crit Care Med. 2006;  34 625-631
• 37 Dargaud Y, Desmurs-Clavel H, Marin S, Bordet J C, Poplavsky J L, Negrier C. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.  J Thromb Haemost. 2008;  6 962-968
• 38 Walenga J M, Hoppensteadt D A. Monitoring the new antithrombotic drugs.  Semin Thromb Hemost. 2004;  30 683-695
• 39 Rost S, Fregin A, Ivaskevicius V et al.. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.  Nature. 2004;  427 537-541
• 40 Wadelius M, Chen L Y, Lindh J D et al.. The largest prospective warfarin-treated cohort supports genetic forecasting.  Blood. 2008;  , June 23 [Epub ahead of print]
• 41 Wilson R F, Mammen E F, Robson M C, Heggers J P, Soullier G, DePoli P A. Antithrombin, prekallikrein, and fibronectin levels in surgical patients.  Arch Surg. 1986;  121 635-640
• 42 Senzolo M, Burra P, Cholongitas E, Burroughs A K. New insights into the coagulopathy of liver disease and liver transplantation.  World J Gastroenterol. 2006;  12 7725-7736
• 43 Bezeaud A, Denninger M H, Dondero F et al.. Hypercoagulability after partial liver resection.  Thromb Haemost. 2007;  98 1252-1256
• 44 Porte R J. Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights.  Semin Thromb Hemost. 1993;  19 191-196
• 45 Abe Y, Wada H, Yamada E et al.. The effectiveness of measuring for fragmented red cells using an automated hematology analyzer in patients with thrombotic microangiopathy.  Clin Appl Thromb Hemost. 2008;  ,  July 3 [Epud ahead of print]
• 46 Cerutti E, Stratta C, Romagnoli R et al.. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation.  Liver Transpl. 2004;  10 289-294
• 47 Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease.  Blood Coagul Fibrinolysis. 1995;  6 S26-S31
• 48 Fujii Y, Sugawa C, Ozawa T, Nakumura R, Brown-Castillo J, Mammen E F. Hemostasis activation during esophageal variceal sclerotherapy with thrombin in cirrhotics.  Am Surg. 1991;  57 222-225